These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11589486)

  • 1. Quantitative viremia test for early prediction of a biochemical response in patients with chronic hepatitis C treated with interferon.
    Nardiello S; Gaeta GB; Pizzella T; Stornaiuolo G; Ascione T; Galanti B; Giusti G
    J Chemother; 2001 Aug; 13(4):424-8. PubMed ID: 11589486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
    Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy.
    Colloredo G; Roffi L; Brunetto MR; Leandro G; Brugnetti B; Bissoli F; Scalori A; Mancia G; Civardi E; Idéo G; Bonino F; Bellati G
    J Viral Hepat; 1999 Sep; 6(5):373-80. PubMed ID: 10607253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low virological response to interferon in children with chronic hepatitis C.
    Pensati P; Iorio R; Botta S; Tuccillo C; Donetto S; Vajro P; Ciarlo G; Vegnente A
    J Hepatol; 1999 Oct; 31(4):604-11. PubMed ID: 10551382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
    Tong MJ; Blatt LM; McHutchison JG; Co RL; Conrad A
    Hepatology; 1997 Dec; 26(6):1640-5. PubMed ID: 9398010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Gallegos-Orozco JF; Loaeza-del Castillo A; Fuentes AP; García-Sandoval M; Soto L; Rodríguez R; Gutiérrez-Ruíz MC; Gutiérrez-Reyes G; Bonder A; Olivera MA; Kershenobich D
    Liver Int; 2005 Feb; 25(1):91-5. PubMed ID: 15698404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial.
    Bresters D; Cuypers HT; Reesink HW; Mauser-Bunschoten EP; van den Berg HM; Schaasberg WP; Wilber JC; Urdea MS; Neuwald P; Lelie PN
    J Med Virol; 1994 Jul; 43(3):262-8. PubMed ID: 7931188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C. Hanshin Chronic Hepatitis C Study Group.
    Wada M; Kang KB; Nishigami T; Shimoyama T
    J Interferon Cytokine Res; 1997 Nov; 17(11):707-12. PubMed ID: 9402109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy of interferon alfa treatment in chronic hepatitis C in relation to the serum concentration of RNA-HCV and the viral genotype].
    Hermida M; Castro A; López S; Vega P; Pedreira J
    An Med Interna; 1997 Oct; 14(10):500-5. PubMed ID: 9424139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
    Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
    Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
    Berg T; Sarrazin C; Herrmann E; Hinrichsen H; Gerlach T; Zachoval R; Wiedenmann B; Hopf U; Zeuzem S
    Hepatology; 2003 Mar; 37(3):600-9. PubMed ID: 12601358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
    J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The factors associated with viral relapse after interferon treatment in chronic hepatitis C patients].
    Ma L; Zhao H; Xie Y; Li MH; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):565-8. PubMed ID: 16938164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.